NCT06827340

Completed

Multiparametric Whole-Body MRI: a Game Changer in Metastatic...

IRCCS Azienda Ospedaliero-Universitaria di Bologna Source

Compare

Other study identifiers

Sponsor study identifier

WB-MRI-2022

Study Type

observational

Actual enrollment (reported)

104

Locations

1 country

Sites

1

Timeline

Study Start

January 1, 1995

Actual (reported)

Primary Completion

April 1, 2024

Actual (reported)

Study Completion

April 1, 2024

Actual (reported)

Brief Summary

WB-MRI is a next-generation imaging technique standardized with the first version of MET-RADs-P guidelines.This narrative review aims to analyse the main scientific evidence available in the literature, explaining what WB MRI is and showing its decisive role in metastatic PC.

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: completed
Actual enrollment (reported): 104 participants
Study completion date: April 1, 2024
Actual (reported)
Listed locations: 1 countries · 1 sites

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

Study Start
January 1, 1995
Actual (reported)
Primary Completion
April 1, 2024
Actual (reported)
Study Completion
April 1, 2024
Actual (reported)
First Submitted
January 10, 2025
Actual (reported)
First Posted
February 14, 2025
Actual (reported)

Last Updated: February 14, 2025
Status Verified: December 2024
Last Update Submitted: February 13, 2025

Conditions

Prostate Cancer (Adenocarcinoma)

Outcome Measures

Primary Outcomes (6)

Identifying the imaging features of metastatic PC in WB-MRI
from 1995 to april 2024
Evaluation of Bone Metastases with WB-MRI
from 1995 to April 2024
Assessment of Nodal Disease
from 1995 to april 2024
Assessment of Visceral Disease
from 1995 to april 2024
Assessing Local Disease and Biochemical Recurrence
from 1995 to april 2024
Response Assessment in Metastatic Prostate Cancer
from 1995 to april 2024

Eligibility Criteria

Age18 Years+

Sexmale

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodProbability Sample

Study Population

Literature with patients with metastatic prostate cancer.

You may qualify if:

"Whole Body MRI"

Sponsors & Collaborators

IRCCS Azienda Ospedaliero-Universitaria di Bologna
Otherlead

Study Sites (1)

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Bologna, Bologna, 40138, Italy

MeSH Terms

Conditions

Prostatic NeoplasmsAdenocarcinoma

Condition Hierarchy (Ancestors)

Genital Neoplasms, MaleUrogenital NeoplasmsNeoplasms by SiteNeoplasmsGenital Diseases, MaleGenital DiseasesUrogenital DiseasesProstatic DiseasesMale Urogenital DiseasesCarcinomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic Type

Study Officials

Lorenzo Bianchi
IRCCS Azienda Ospedaliero-Universitaria di Bologna
PRINCIPAL INVESTIGATOR

Enrollment

104 participants (actual enrollment reported by the registry).

Study Design

Study Type: observational
Observational Model: COHORT
Time Perspective: RETROSPECTIVE
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

January 10, 2025

First Posted

February 14, 2025

Study Start

January 1, 1995

Actual (reported)

NCT02853110

Hypofractionated Focal Lesion Ablative Microboost in prostatE Cancer

Phase 2Completed

NCT06931496

Evaluation of the PROSTia Test in Patients Undergoing Prostate Biopsy

Not ApplicableNot Yet Recruiting

NCT03852654

18F-DCFPyL PET-CT Scan and Prostate Cancer

Phase 2/3Unknown

NCT07209878

68Ga-PSMA-11 PET Imaging for Diagnosing Prostate Cancer, a Head-to-head Comparison With mpMRI

Phase 2/3Recruiting

NCT07363382

The Value of GRPR PET Imaging for Diagnosis and Staging in Prostate Cancer

Phase 1/2Recruiting

NCT06820333

Impact of [18F] PSMA-1007 Imaging for Primary Staging of Prostate Cancer

Recruiting

"Diffusion Weighted Imaging"

"PET-CT and WB-MRI"

"Metastatic Prostate Cancer"

"Biochemical Recurrence in Metastatic Prostate Cancer"

"DWIBS"

"Multiparametric MRI"

"response assessment in metastatic prostate cancer"

"Dixon Method",

"bone biopsy in metastatic prostate cancer",

"bone metastases in prostate cancer",

"MET-RADs".

analysis from 1995 to April 2024.

You may not qualify if:

duplicates
repetitive,
irrelevant,
unrelated,
out-of-date guidelines,
case reports

Contact the study team to confirm eligibility.

Primary Completion

April 1, 2024

Actual (reported)

Study Completion

April 1, 2024

Actual (reported)

Last Updated

February 14, 2025

Record last verified: 2024-12

Data Sharing

IPD Sharing: Will not share

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT06827340
Data provider: ClinicalTrials.gov
Source updated: 2025-02-14
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:25:25 UTC

Locations

IT(1)

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

Primary Completion

Study Completion

First Submitted

First Posted

Conditions

Outcome Measures

Primary Outcomes (6)

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations